Formed in 2019, Sionna's most recent financing was a $182 million third round that closed last year, which followed a $111 ...

The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer ...

Meanwhile, according to Seeking Alpha data, its average price target of analysts is $61.01, suggesting a potential upside of about 8.4% from the current share price. In this article, dear Seeking ...

在最新一期的“Letter From the Chairman”中，CI Games的老板Chris Roberts谈到了《星际公民》的Alpha 4.0版本，透露了一些游戏相关的情报，一起来了解下。

After hours: January 30 at 6:25:01 PM EST Loading Chart for AOSL ...

Pursuant to the transaction with Telix, ImaginAb has retained its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical ...

Hennion & Walsh Asset Management Inc. cut its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 14.3% during the 4th quarter, according to its most recent Form 13F filing with ...

After hours: January 29 at 5:10:30 PM EST Loading Chart for PTGX ...

We use cookies on your device to help us provide a more reliable service, show you relevant adverts and create more shows you might like. Find out more atchannel4.com ...

On behalf of the ATVB editors and Digital Strategies Team, we are excited to announce the launch of ATVB_Net, a new communication style, from the ATVB journal. Check back regularly for author ...

The Witcher 4 has now been officially revealed, with a new trailer confirming that the game will focus on Ciri as the main protagonist. This latest look does give us an idea as to the overall ...